Clinical Significance of P-Glycoprotein Immunohistochemistry and Histomorphologic Factors in Patients with Osteosarcoma

AUTHORS

Sara Pakbaz 1 , * , S Torabi-Nezhad 2 , F Mojtahed Jaberi 2 , MJ Saalabian 2 , S Rezazadeh 2

1 Department of Pathology, Shiraz Medical School, Shiraz University of Medical Sciences, [email protected], Fars, Iran

2 Department of Pathology,Shiraz University of Medical Sciences, Fars, Iran

How to Cite: Pakbaz S, Torabi-Nezhad S, Mojtahed Jaberi F, Saalabian M, Rezazadeh S. Clinical Significance of P-Glycoprotein Immunohistochemistry and Histomorphologic Factors in Patients with Osteosarcoma, Iran Red Crescent Med J. Online ahead of Print ; 11(3):277-285.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 11 (3); 277-285
Article Type: Research Article
Received: January 28, 2009
Accepted: May 17, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Osteosarcoma is the most frequent highly malignant bone tumor with a peak incidence in the second decade of life. Although survival rate increased up to 60-70% within the last 10 years, the problem of unresponsiveness to chemotherapy remains. In this study, we sought to determine the prognostic significance of P-glycoprotein as a tumor marker for osteosarcoma.

 

Methods: In a retrospective study, we correlated P-glycoprotein immunostaining with clinicopathologic and histomorphologic features of the tumor and the patient outcome in 30 cases with primary, non-metastatic, high-grade osteosarcoma who were homogeneously treated.

 

Results: P-glycoprotein positivity was found in 14 of 30 cases and was significantly associated with a higher incidence of adverse events and relapse rate. No relationship was found between p-glycoprotein immunostaining and clinicopathologic features such as age, sex, tumor site, histologic subtype, osteoid content, osteoid pattern, pretreatment necrosis, pleomorphism of the cells, and presence of prominent nucleoli, except for mitotic activity per 10 HPF.

 

Conclusions: P-glycoprotein positivity in immunohistochemistry should be taken into consideration to identify a subgroup of osteosarcoma patients with poor outcome at the time of diagnosis. So it might be an important marker in planning innovative chemotherapeutic regimens.

 

Keywords

Osteosarcoma Prognosis Immunohistochemistry P-glycoprotein

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: